Shooting at the DARC: potential issues with species-specific antimalarials.

I Woolley1, K Horne

  • 1Department of Infectious Diseases, Monash Medical Centre, Monash University, Clayton, Victoria, Australia. ian.woolley@monash.edu

Summary

Novel drug design offers targeted malaria treatment by blocking cellular entry. CCR5 blockers, used for HIV, show potential against Plasmodium vivax malaria by inhibiting red blood cell invasion, possibly reducing drug resistance.